

Table I. Physico-chemical properties of kobutimycins A (1) and B (2).

	Kobutimycin A	Kobutimycin B
Appearance	Colorless oily substance	Colorless oily substance
Molecular formula	C ₁₉ H ₂₅ NO ₅	C ₂₀ H ₂₇ NO ₅
HRFAB-MS (<i>m/z</i>)		
Found:	348.1805 (M+H) ⁺	362.1967 (M+H) ⁺
Calcd:	348.1811	362.1968
[α] _D ²² (c 1.0, CHCl ₃)	+88.2	+107.2
UV λ _{max} ^{MeOH} nm (ε)	212.0 (5,600), 256.8 (14,500)	207.6 (7,100), 256.8 (16,100)
λ _{max} ^{MeOH-HCl} nm (ε)	230.0 (11,700), 321.8 (11,500)	232.0 (12,900), 322.8 (12,800)
λ _{max} ^{MeOH-NaOH} nm (ε)	219.6 (sh, 6,800), 258.4 (16,300)	211.2 (7,000), 257.6 (15,400)
IR (KBr) cm ⁻¹	2980, 2950, 1740, 1660, 1380, 1240, 1160, 1060, 920	2980, 2950, 1740, 1660, 1380, 1240, 1180, 1150, 1070, 920
Solubility		
Soluble:	<i>n</i> -Hexane, CHCl ₃ , EtOAc, MeOH, CH ₃ COCH ₃	<i>n</i> -Hexane, CHCl ₃ , EtOAc, MeOH, CH ₃ COCH ₃
Insoluble:	H ₂ O	H ₂ O
TLC ^a (Rf value) (I)	0.20	0.21
(II)	0.48	0.50
HPLC ^b (Rt, minutes)	4.82	6.42
HVPE ^c		
(Rm value, alanine=1.0)	0.82	0.80

^a Silica gel TLC (Merck Art 5715), solvent system (I) CHCl₃ - MeOH (100:1) (II) EtOAc.

^b Column, Capcell Pak C18 SGI20 4.6×150 mm (Shiseido); mobile phase, MeOH - H₂O (70:30); flow rate, 1.0 ml/minute; detection, UV 254 nm.

^c HVPE in HCOOH - CH₃COOH - H₂O (1:3:36) under 2000 V for 30 minutes.

Table 2. ¹H and ¹³C NMR spectral data of kobutimycins A (1) and B (2) (400 MHz and 100 MHz, respectively, in CDCl₃).

Position	Kobutimycin A		Kobutimycin B	
	δ _C (ppm)	δ _H (ppm, <i>J</i> in Hz)	δ _C (ppm)	δ _H (ppm, <i>J</i> in Hz)
1a	60.6	4.42 br s*	60.6	4.42 br s
2	22.2	1.63, dt, <i>J</i> =5.6, 12.6, 14.8, 2.24 m, <i>J</i> =5.5, 14.8	22.2	1.63 m, 2.24 m, <i>J</i> =14.8
3	44.0	3.66 dt, <i>J</i> =5.5, 12.6, 3.80 dd, <i>J</i> =5.5, 15.1	44.0	3.66 dt, <i>J</i> =5.6, 12.4, 3.80 dd, <i>J</i> =5.6, 15.4
4a	171.2		171.2	
5	144.4		144.4	
5-CH ₃	11.9	1.98 s	11.9	1.98 s
6	143.1	6.82 br s	143.1	6.82 br s
7	140.1		140.1	
7a	55.3		55.2	
1'	118.4	5.46 d, <i>J</i> =10.0	118.5	5.46 d, <i>J</i> =10.0
2'	68.4	5.74 dd, <i>J</i> =3.8, 10.0	68.3	5.75 dd, <i>J</i> =4.0, 10.0
3'	70.9	4.91 m, <i>J</i> =3.8, 6.6	71.0	4.91 m, <i>J</i> =4.0, 6.0
4'	14.5	1.24 d, <i>J</i> =6.6	14.5	1.24 d, <i>J</i> =6.0
3'-OC(=O)	170.5		170.5	
3'-OC(=O)-CH ₃	21.0	2.00 s	21.0	2.00 s
1''	175.5		175.1	
2''	34.0	2.53 m, <i>J</i> =6.9	41.1	2.36 m, <i>J</i> =7.2
3''	18.7	1.14 d, <i>J</i> =6.9	16.6	1.13 d, <i>J</i> =7.2
2''-CH ₃	19.0	1.16 d, <i>J</i> =6.9	—	—
2''-CH ₂	—	—	26.6	1.45 m, <i>J</i> =6.6, 1.66 m
2''-CH ₂ CH ₃	—	—	11.5	0.89 t, <i>J</i> =7.8

* Multiplicity.

Fig. 2. Summary of the CH long range couplings (\rightarrow) observed in the HMBC spectrum of kobutimycin A.




Table 3. Antimicrobial spectrum of kobutimycins A (1) and B (2).

Test organisms	MIC ($\mu\text{g/ml}$)		
	Medium*	1	2
<i>Staphylococcus aureus</i> FDA 209P	a	25	25
<i>Micrococcus luteus</i> IFO 3333	a	12.5	12.5
<i>Bacillus subtilis</i> PCI 219	a	25	25
<i>Escherichia coli</i> K-12	a	> 100	> 100
<i>Klebsiella pneumoniae</i> PCI 602	a	> 100	> 100
<i>Candida albicans</i> 3147	b	> 100	> 100
<i>Saccharomyces cerevisiae</i> F-7	b	50	50
<i>Pyricularia oryzae</i>	b	50	50
<i>Rhizoctonia solani</i>	b	12.5	50
<i>Rosellinia necatrix</i>	c	3.1	12.5
<i>Phomopsis fukushii</i> PF-6B-1	c	50	50

* a: Mueller-Hinton agar (Difco), 37°C, 18 hours.
b: Nutrient agar + glucose 1%, 27°C, 42 hours.
c: Potato-sucrose agar, 27°C, 4 days.

6-H (δ 6.82) and 1'-H (δ 5.46). These NOEs revealed that relative position between the chromophore and the side chain.

Based on these results, the total planar structure of **1** was determined to be (7*Z*)-5-methyl-7-[2'-(2''-methylpropionyloxy)-3'-acetoxy]butylidene-1a,2,3,7-tetrahydrocyclopent[*b*]oxireno[*c*]pyridine (Fig. 1). The ^1H and ^{13}C NMR spectra of **2** were quite similar to those of **1** except the proton signals at high field region. The NMR experiments of **2** suggested the presence of a 2-methylbutyryl group instead of the 2-methylpropionyl group of **1**. Thus, the structure of **2** was determined as shown in Fig. 1.

Kobutimycins are structurally similar to the

known alkaloid antibiotics such as abikoviromycin (latumcidin)¹⁻³, dihydrolatumcidin⁴, *n*-hydroxy dihydroabikoviromycin⁵ and hatomamicin⁶.

The antimicrobial activity of kobutimycins were tested according to the agar dilution method with two-fold dilution. The results are summarized in Table 3. Kobutimycins showed weak activity against Gram-positive bacteria, and some phytopathogenic fungi. Cytotoxicities against lymphoid leukemia L1210 with IC_{50} value were 0.19 $\mu\text{g/ml}$ in **1** and 0.11 $\mu\text{g/ml}$ in **2**.

Acknowledgments

The authors wish to thank Mr. KATSUHISA YAMAZAKI (Institute for Chemotherapy) for cytotoxicity assays.

KENJI KANBE
HIROSHI NAGANAWA
YOSHIRO OKAMI
TOMIO TAKEUCHI

Institute of Microbial Chemistry,
3-14-23 Kamiosaki, Shinagawa-ku,
Tokyo 141, Japan

(Received May 11, 1992)

References

- GUREVICH, A. I.; M. N. KOLOSOV, V. G. KOROBKO & V. V. ONOPRIENKO: The structure of abikoviromycin. *Tetrahedron Lett.* 18: 2209~2212, 1968
- UMEZAWA, H.; T. TAZAKI & S. FUKUYAMA: An antiviral substance, abikoviromycin, produced by *Streptomyces* species. *J. Antibiotics* 5: 469~476, 1952
- SAKAGAMI, Y.; R. UTAHARA, K. YAGISHITA & H. UMEZAWA: Identity of latumcidin with abikoviromycin. *J. Antibiotics, Ser. A* 11: 231~232, 1958
- SETO, H.; T. SATO, H. YONEHARA & W. C. JANKOWSKI: Application of carbon-13 in biosynthetic studies; FT- ^{13}C nuclear magnetic resonance spectra of dihydrolatumcidin. *J. Antibiotics* 26: 609~611, 1973
- TAKAHASHI, S.; K. SERITA, R. ENOKITA, T. OKAZAKI & T. HANEISHI: A new antibiotic, *N*-hydroxy-dihydroabikoviromycin. *Annu. Rep. Sankyo Res. Lab.* 38: 105~108, 1986
- IMAI, H.; S. FUJITA, K. SUZUKI, M. MORIOKA, T. TOKUNAGA, M. SHIMIZU, S. KADOTA, T. FURUYA & T. SAITO: Hatomamicin (YL-0358M-A), a new alkaloid antibiotic: Fermentation, isolation, structure, and biological properties. *J. Antibiotics* 42: 1043~1048, 1989